Soukup J, Doenicke A, Hoernecke R, Vorhammer B, Seebauer A, Moss J
Klinik für Anaesthesiologie und operative Intensivmedizin, Martin-Luther-Universitäte Halle-Wittenberg.
Anaesthesist. 1996 Nov;45(11):1024-9. doi: 10.1007/s001010050335.
Cisatracurium-one of the ten stereoisomers of atracurium-is an intermediate long-acting non-depolarizing neuromuscular blocking agent. Cardiovascular reactions have been described after administration of cisatracurium or vecuronium in surgical patients.
After approval by our institutional review board, 62 patients (ASA I-II) were randomly assigned to three groups to either receive 3xED95 or 5xED95 of cisatracurium or 3xED90 of vecuronium prior to intubation as a bolus. After oral premedication with 2 mg lormetazepam anaesthesia was induced with thiopental (4-12 mg/kg) and maintained with O2/N2O and isoflurane (1.5%-2%). Six minutes after administration of thiopental, patients received the muscle relaxant. Six minutes later 0.1-0.2 mg fentanyl was given and the trachea was intubated. Heart rate (HR) and blood pressure (BP) were monitored every minute. Changes of heart rate or blood pressure > 20% compared to baseline were defined as clinically significant.
After application of the study drug, median values of blood pressure and heart rate were stable. For each muscle relaxant, there were several patients who had statistically significant cardiovascular changes. After 3xED95 cisatracurium, 3 of 21 patients exhibited haemodynamic changes > 20% (2 exhibited hypotension and 1 tachycardia), while in the high-dose cisatracurium group 2 of 21 patients demonstrated a tachycardia that was predetermined to be statistically but not clinically significant. In the vecuronium group, 2 of 20 patients sustained statistically significant hypotension and 1 patient had statistically significant tachycardia. The frequency of all individual cardiovascular changes after the application of the muscle relaxant was not dose-dependent.
After the administration of cisatracurium in two different doses (3xED95 and 5xED95) or vecuronium (3xED90) only minor cardiovascular changes were observed. Both drugs proved to be safe for use during induction of anaesthesia in patients ASA I-II. With regard to its cardiovascular effects, cisatracurium shares with vecuronium the requirements of an ideal muscle relaxant.
顺式阿曲库铵——阿曲库铵的十种立体异构体之一——是一种中长效非去极化型神经肌肉阻滞剂。在外科手术患者中,已有人描述过使用顺式阿曲库铵或维库溴铵后的心血管反应。
经我们机构审查委员会批准,62例患者(美国麻醉医师协会分级I-II级)被随机分为三组,在插管前分别给予3倍有效剂量95%(ED95)或5倍有效剂量95%的顺式阿曲库铵,或3倍有效剂量90%(ED90)的维库溴铵作为单次推注。在口服2mg氯美扎酮进行术前用药后,用硫喷妥钠(4-12mg/kg)诱导麻醉,并用氧气/氧化亚氮和异氟烷(1.5%-2%)维持麻醉。在给予硫喷妥钠6分钟后,患者接受肌肉松弛剂。6分钟后给予0.1-0.2mg芬太尼,然后进行气管插管。每分钟监测心率(HR)和血压(BP)。与基线相比,心率或血压变化>20%被定义为具有临床意义。
应用研究药物后,血压和心率的中位数稳定。对于每种肌肉松弛剂,都有几名患者出现了具有统计学意义的心血管变化。给予3倍有效剂量95%的顺式阿曲库铵后,21例患者中有3例出现血流动力学变化>20%(2例出现低血压,1例出现心动过速),而在高剂量顺式阿曲库铵组中,21例患者中有2例出现心动过速,经预先设定,该心动过速具有统计学意义但无临床意义。在维库溴铵组中,20例患者中有2例出现具有统计学意义的低血压,1例患者出现具有统计学意义的心动过速。应用肌肉松弛剂后所有个体心血管变化的频率与剂量无关。
给予两种不同剂量(3倍有效剂量95%和5倍有效剂量95%)的顺式阿曲库铵或维库溴铵(3倍有效剂量90%)后仅观察到轻微的心血管变化。这两种药物在ASA I-II级患者麻醉诱导期间使用均被证明是安全的。就其心血管效应而言,顺式阿曲库铵与维库溴铵一样符合理想肌肉松弛剂的要求。